The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Highlights in myeloma from BSH
Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, shares his highlights from this year’s BSH meeting. Prof. Pratt first comments on the new BSH guidelines for the treatment of multiple myeloma, as well as updates on ongoing UK clinical trials in myeloma. Moving forward, Prof. Pratt mentions presentations on amyloidosis, COVID-19 vaccination in patients with hematological malignancies, and promising data on teclistamab and iberdomide. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
